Endocrine and metabolic manifestations in inflammatory bowel disease

Annals of Gastroenterology

Volumn 25, Issue 1, 2012, Pages 37-44

  Tigas, Stelios ^a   Tsatsoulis, Agathocles ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Growth failure; Hypogonadism; Inflammatory bowel disease; Insulin resistance; Lipids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTRADIOL; GESTAGEN; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GROWTH HORMONE; IBANDRONIC ACID; INFLIXIMAB; INSULIN; MERCAPTOPURINE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE[1-34]; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; CROHN DISEASE; DELAYED PUBERTY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENTERITIS; FEMUR FRACTURE; GROWTH RETARDATION; HUMAN; HYPOGONADISM; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC BONE DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OSTEOPOROSIS; PATHOGENESIS; REMISSION; SCREENING TEST; VITAMIN SUPPLEMENTATION;

EID: 84856827310     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-2078.
3. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-1122.
4. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011; 7:235-241.
5. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-4831.
6. Voulgari P V. Rheumatological manifestations in inflammatory bowel disease. Ann Gastroenterol 2011;24:173-180.
7. Katsanos KH, Tsianos EV. The kidneys in inflammatory bowel disease. Ann Gastroenterol 2002;15:41-52.
8. Karamanolis G P. Cutaneous and ocular manifestations of IBD. Ann Gastroenterol 2006;19:181-183.
9. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 2009;122:599-604.
10. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795-841.
11. van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006;243:59-64.
12. Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007;5:721-728.
13. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:857-864.
14. Mazziotti G, Angeli A, Bilezikian J P, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17:144-149.
15. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:113-121.
16. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006;12:1162-1174.
17. Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991;54:548-552.
18. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 2004;23:161-170.
19. Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008;149:4799-4808.
20. Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-477.
21. Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99:2178-2185.
22. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008;52:867-874.
23. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-233.
24. Lin CL, Moniz C, Chambers TJ, Chow J W. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996;111:1263-1271.
25. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007;13:416-423.
26. Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:1261-1272.
27. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-487.
28. Lewis, NR, Scott, BB. Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease. London: British Society of Gastroenterology 2007; Available at: http://www.bsg.org.uk/clinical-guidelines/ibd/guidelines-for-osteoporosis-in-inflammatory-bowel-disease-and-coeliac-disease.html
29. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
30. Lewiecki EM. Premenopausal bone health assessment. Curr Rheumatol Rep 2005;7:46-52.
31. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397.
32. Goodhand JR, Kamperidis N, Nguyen H, Wahed M, Rampton DS. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011;33:551-558.
33. Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med 1996;156:1133-1134.
34. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008;30:1146-1148.
35. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
36. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-2294.
37. Heuschkel R, Salvestrini C, Beattie M, Hildebrand H, Walters T, Griffiths A. Guidelines for the Management of Growth Failure in Childhood Inflammatory Bowel Disease. Inflamm Bowel Dis 2008;14:839-849.
38. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988;95:1523-1527.
39. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994;18:165-173.
40. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006;118:124-129.
41. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:373-380.
42. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm Bowel Dis 2007;13:620-628.
43. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos E V. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001;11:364-367.
44. Savage MO. Growth-promoting hormone therapy in inflammatory bowel disease. JPGN 2010;51:S135-S136.
45. McLain BI, Davidson PM, Stokes KB, Beasley S W. Growth after gut resection for Crohn's disease. Arch Dis Chil 1990;65:760-762.
46. Varille V, Cézard J P, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1996;23:13-19.
47. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-430.
48. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011;52:31-37.
49. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005;(3):CD003873.
50. Kirschner BS, Klich JR, Kalman SS, deFavaro M V, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981;80:10-15.
51. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996;25:699-717.
52. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993;34:939-943.
53. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993;105:681-691.
54. Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004;39:15-27.
55. Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996;12:151-158.
56. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996;38:543-548.
57. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989;97:905-910.
58. Moeeni V, Day AS. Impact of inflammatory bowel disease upon growth in children and adolescents. ISRN Pediatrics 2011:365712.
59. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
60. Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr 2008;153:651-658.
61. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-135.
62. Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001;281:R1483-R1491.
63. Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 1999;10:201-217.
64. Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997;37:50-63.
65. Warren M P, Voussoughian F, Geer EB, Hyle E P, Adberg CL, Ramos RH. Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. J Clin Endocrinol Metab 1999;84:873-877.
66. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998;12:21-25.
67. Klaus J, Reinshagen M, Adler G, Boehm B, von Tirpitz C. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. BMC Gastroenterol 2008;8:48.
68. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205-210.
69. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:83-100.
70. Hudson M, Flett G, Sinclair TS, Brunt P W, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997;58:229-237.
71. Timmer A, Bauer A, Dignass A, Rogler G. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 2007;5:87-94.
72. Peppercorn MA. Fertility, pregnancy, and nursing in inflammatory bowel disease. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011.
73. Agouridis A P, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol 2011;24:181-187.
74. Akerlund JE, Reihner E, Angelin B, et al. Hepatic metabolism of cholesterol in Crohn's disease. Effect of partial resection of ileum. Gastroenterology 1991;100:1046-1053.
75. Koutroubakis IE, Malliaraki N, Vardas E, et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol 2001;13:1415-1419.
76. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:209-217.
77. Bregenzer N, Hartmann A, Strauch U, et al. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis 2006;12:53-56.
78. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21:283-288.
79. Lees C W, Barrett JC, Parkes M, J Satsangi. New IBD genetics: common pathways with other diseases. Gut 2011;60:1739-1753.
80. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81-93.
81. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007;56:577-583.
82. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55:1341-1349.
83. Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin--implications for inflammatory bowel disease. Mol Nutr Food Res 2008;52:855-866.
84. Hontecillas R, Horne WT, Climent M, et al. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol 2011;4:304-313.
85. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688-695.
86. Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009;25:172-181.
87. Mohapatra SK, Guri AJ, Climent M, et al. Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One 2010;5:e10215.
88. Lund JL, Stürmer T, Porter CQ, Sandler RS, Kappelman MD. Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data. Inflamm Bowel Dis 2011;17:787-794.